Investigating the role of ctDNA in advanced thyroid cancer
A Multicentre Prospective Study Investigating the Utility of ctDNA as a Biomarker of Disease Burden, Genetic Heterogeneity and Tumour Evolution in Advanced Thyroid Cancer
This study is trying to see if analyzing blood samples for tumor DNA can help doctors better understand and treat advanced thyroid cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT05837260 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the utility of circulating tumor DNA (ctDNA) and tumor evolution in patients with advanced thyroid cancer. It will collect blood and tissue samples from participants to analyze genetic markers and tumor biomarkers that may indicate disease progression and treatment response. By understanding the genetic landscape of these tumors, the study seeks to improve personalized treatment strategies and patient stratification. The research will focus on various types of thyroid cancer, including differentiated, medullary, and anaplastic thyroid cancers.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with specific types of advanced thyroid cancer, including radioiodine refractory differentiated thyroid carcinoma, medullary thyroid cancer, or anaplastic thyroid cancer.
Not a fit: Patients with early-stage thyroid cancer or those not diagnosed with the specified advanced forms of thyroid cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized treatment options for patients with advanced thyroid cancer.
How similar studies have performed: Other studies have shown promise in using ctDNA for monitoring cancer progression, suggesting that this approach may yield valuable insights in thyroid cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older. (all cohorts) * Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1) * Patients with newly diagnosed resectable locally advanced medullary thyroid cancer Or Patients with newly diagnosed metastatic medullary thyroid cancer for surveillance Or Patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2) * Patients with RR-DTC starting systemic therapy Or Patients with RR-DTC on systemic therapy Or Patients with MTC starting systemic therapy Or Patients with MTC on systemic therapy (cohort 3) * Patients with newly diagnosed anaplastic thyroid cancer (cohort 4) * Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts) * Patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts) * Ability to give informed consent for biological sample collection. (all cohorts) Exclusion Criteria: * Previous or concurrent illness, which in the investigator's opinion would interfere with collection of the complete sample collection * Any invasive malignancy within previous 5 years (other than non-melanomatous skin carcinoma or carcinoma in situ) * Pregnancy
Where this trial is running
London
- The Royal Marsden NHS Foundation Trust — London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Kate Newbold — Royal Marsden NHS Foundation Trust
- Study coordinator: Leslie Cheng
- Email: leslie.cheng@rmh.nhs.uk
- Phone: 02000000000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.